|
Jun 20
|
Dermtech files for Chapter 11, lays off 20% of staff
|
|
May 14
|
DermTech Reports First-Quarter 2024 Financial Results
|
|
Apr 19
|
Cancer test maker Dermtech to cut 100 jobs, explore strategic options
|
|
Apr 18
|
DermTech to Explore Strategic Alternatives and Implement Restructuring Plan
|
|
Mar 8
|
DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology
|
|
Mar 2
|
DermTech, Inc. (NASDAQ:DMTK) Q4 2023 Earnings Call Transcript
|
|
Feb 29
|
DermTech, Inc. (DMTK) Reports Q4 Loss, Misses Revenue Estimates
|
|
Feb 29
|
DermTech Reports Fourth-Quarter 2023 Financial Results
|
|
Feb 13
|
DermTech Announces Release Date for Fourth-quarter 2023 Financial Results
|
|
Jan 16
|
DermTech (NASDAQ:DMTK) Will Have To Spend Its Cash Wisely
|
|
Jan 16
|
DermTech Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-on Assay
|
|
Jan 8
|
DermTech Announces Positive Topline Results From Trust 2 Study Evaluating the DermTech Melanoma Test (DMT)
|
|
Nov 3
|
DermTech, Inc. (NASDAQ:DMTK) Q3 2023 Earnings Call Transcript
|
|
Nov 2
|
DermTech Inc (DMTK) Reports 10% Increase in Total Revenue for Q3 2023
|
|
Nov 2
|
DermTech Reports Third-Quarter 2023 Financial Results
|
|
Aug 25
|
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Jun 28
|
DermTech Announces Restructuring to Prioritize Growth Opportunities and Streamline Operations
|
|
Jun 20
|
If You Own These 3 Growth Stocks, You Might Want to Rethink Your Position
|